CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
========================================================================================================================================

* Jing Gao
* Zhengyi Wang
* Wenqing Jiang
* Yanni Zhang
* Zhen Meng
* Yanling Niu
* Zhen Sheng
* Chan Chen
* Xuejun Liu
* Xi Chen
* Chanjuan Liu
* Keren Jia
* Cheng Zhang
* Haiyan Liao
* Jaeho Jung
* Eunsil Sung
* Hyejin Chung
* Jingwu Z. Zhang
* Andrew X. Zhu
* Lin Shen